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Leukotrienes (LTs) are potent lipid mediators, first described in 1979 by Borgeat and Samuelsson (5) as a new lineage of arachidonic acid-derived metabolites. LTs are produced by, recruit, and activate immune cells, thus initiating, augmenting, and sustaining tissue inflammation. The concerted action of 5-lipoxygenase (5-LPO) and 5-LPO-activating protein (FLAP) on arachidonic acid produces LTA 4 , which is converted either by LTA 4 hydrolase (LTA4H) to LTB 4 or is conjugated with reduced glutathione by LTC 4 synthase to produce cysteinyl (cys) LTs (LTC 4 , LTD 4 , and LTE 4 ) (32) (illustrated in Fig. 1 ). 5-LPO activity requires perinuclear translocation from the cytosol (9) and association with FLAP homodimer (7, 27, 39) and is increased by phosphorylation at serine 271 (55) . LTB 4 and cysLTs exert their actions by binding to distinct G proteincoupled receptors: BLT1 and BLT2 for LTB 4 , and cysLT 1 and 2 receptors (cysLT 1 R and cysLT 2 R) for cysLTs ( Fig. 1) . LTB 4 is a particularly potent chemoattractant for multiple inflammatory cell types, especially neutrophils and macrophages. Due to the wide-ranging pathological effects of LTs, including increased production of matrix proteins, increased smooth muscle contractility and proliferation, and enhanced cell survival, critical roles have been proposed for a number of lung disorders, including asthma, pulmonary fibrosis, and chronic PHT (36, 50) .
A critical role for LTs has been established in adult rat models of chronic PHT (49 -51, 54) and is suggested by observational studies in adult humans with primary PHT (50, 51, 56) and in newborn infants with evolving or established BPD (10, 16, 20, 45) . In neonatal animals, LTB 4 receptor blockade prevented acute hyperoxic lung injury in preterm guinea pigs (37) , and a 5-LPO inhibitor decreased lung inflammation and edema induced by saline lavage in newborn piglets (1) . Inhibitors of 5-LPO or FLAP prevented inhibited alveolar development secondary to severe hyperoxia (6) , whereas montelukast (a cysLT 1 R antagonist) had no effect on chronic neonatal lung injury secondary to moderate hyperoxia (21) in neonatal rats. In premature human infants with evolving BPD, LTB 4 and LTE 4 were increased in tracheal aspirate fluid (16) and urine (20, 45) , respectively. Ex-premature infants with severe BPD also had increased urinary LTE 4 (10) . Montelukast given as preventive therapy in at-risk preterm infants did not reduce the incidence of moderate-severe BPD (25) ; however, when employed as rescue therapy for severe late-stage BPD, it conferred a survival advantage (42) . Increased cysLTs have also been reported in tracheal aspirates of infants with persistent PHT of the newborn, an acute form of PHT (48) . However, the specific role of various LTs in the pathogenesis of chronic neonatal PHT, particularly in the context of BPD or experimental BPD-like lung injury, has not been previously studied.
Bleomycin sulfate is a chemotherapeutic agent that produces a dose-dependent pulmonary inflammatory and fibrotic response when administered systemically or intratracheally (4, 24) . In neonatal rats, our laboratory and others have reported that repeated systemic administration of bleomycin leads to a selective decrease in lung growth, along with arrested alveolarization, vascular hypoplasia, and chronic PHT (15, 30, 44, 52) , similar to the lung pathology observed in human infants with severe BPD. We have employed this model to demonstrate a critical role for macrophage influx and macrophagederived tumor necrosis factor (TNF)-␣ in the pathogenesis of chronic PHT (26, 44) . In the present study, we hypothesized that LTs are upregulated in bleomycin-induced lung injury, and that inhibition of LT biosynthesis or signaling would attenuate inflammation and consequent chronic PHT. Our observations reported herein suggest a critical role for LTB 4 , but not for cysLTs, in experimental chronic neonatal PHT.
MATERIALS AND METHODS

Materials.
Bleomycin sulfate was purchased from Calbiochem (San Diego, CA). Zileuton, montelukast, and C18 solid-phase extraction cartridges (catalog no. 400020) were purchased from Cayman Chemical (Ann Arbor, MI). SC57461A was purchased from Tocris Biosciences (Bristol, UK). Acids, alcohols, organic solvents, paraformaldehyde, Permount, and Superfrost/Plus microscope slides were from Fisher Scientific (Whitby, ON, Canada). Weigert's resorcinfuchsin stain was from Rowley Biochemical (Danvers, MA). Antichemokine (C-C motif) ligand 4 (CCL4) (catalog no. sc-393441), anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; catalog no. sc-25778), and anti-FLAP (catalog no. sc-28815) were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-cluster of differentiation (CD) 68 (catalog no. MCA341R) was from Serotec (Raleigh, NC). Anti-TNF-␣ (catalog no. HP8001) was from Hycult Biotech (Uden, The Netherlands). Anti-5-LPO (catalog no. 3289), anti-phospho-serine 271 5-LPO (catalog. no. 3748), and goat anti-rabbit IgG-peroxidase antibody were from Cell Signaling Technology (Beverly, MA). Anti-LTA4H (catalog no. NBP1-96835) was purchased from Novus Biologicals (Littleton, CO). Anti-myeloperoxidase (MPO; catalog. no. A0398) was from DAKO Agilent (Mississauga, Ontario, Canada). ELISA kits for LTB 4 (catalog no. ADI-900-068) and cysLTs (catalog no. ADI-900-070) were from Enzo Life Sciences (Farmingdale, NY). Tris-glycine precast gels and polyvinylidene difluoride (PVDF) membranes were from Thermo Scientific (Rockford, IL). Unless otherwise specified, all other chemicals and reagents were from Bioshop Canada (Burlington, Ontario, Canada).
Animal exposures and interventions. All procedures involving animals were performed in accordance with the standards of the Canadian Council on Animal Care and were approved by the Animal Care Committee of the Hospital for Sick Children Research Institute. Timed-pregnant Sprague-Dawley dams were purchased from Taconic Farms (Germantown, NY). Commencing on the day after birth, pups received 1 mg/kg bleomycin sulfate (0.2 mg/ml suspended in 0.9% saline ϩ 20% DMSO; 5 l/g body wt by 27G needle in the right iliac fossa) or 0.9% saline ϩ 20% DMSO (control) daily intraperitoneally for 14 days, as previously described (30) , with or without zileuton (5-LPO inhibitor), montelukast (cysLT 1R antagonist), or SC57461A (LTA4H inhibitor; all at 2 mg/ml ϭ 10 mg/kg) (see Fig. 1 ). For zileuton, dose-response studies (5, 10, or 20 mg/kg ip daily) were conducted, demonstrating maximal inhibitory effect on lung macrophage influx at 10 mg/kg (data not shown). For both montelukast and SC57461A, which are orally active, the intraperitoneal route of delivery was necessitated by an inability to safely perform daily gavage in newborn rats. For montelukast, dose-response studies (1, 5, or 10 mg/kg ip daily) were conducted, with the lowest dose based on a previous negative study in neonatal rats (1 mg/kg ip daily) (21) . These studies demonstrated maximal inhibitory effect on lung CCL4 content at 10 mg/kg (data not shown). For SC57461A, dose-response studies were conducted using a range of doses surrounding 10 mg/kg (5, 10, and 20 mg/kg ip daily) based on equivalence of IC50 with zileuton and similar oral bioavailability (2) . These studies demonstrated maximal inhibitory effect of SC57461A on lung LTB4 content at 10 mg/kg (data not shown), the same (orally administered) dose and dose interval reported to have inhibitory effects on inflammatory injury in adult rodents (22) . Each litter was maintained at n ϭ 10 -12 pups to control for nutritional effects. At the end of each 7-or 14-day exposure period, pups either were killed by pentobarbital overdose, or were exsanguinated after anesthesia.
Cardiac ventricular weights. Right ventricular (RV) hypertrophy was quantified by measuring the RV-to-left ventricle and septum dry weight ratio (Fulton index), as previously described (19) .
Two-dimensional echocardiography-derived measurements of pulmonary hemodynamics. Pulmonary vascular resistance (PVR) was evaluated noninvasively using two-dimensional echocardiography and Doppler ultrasound (Vivid 7 cardiac ultrasound system and I13L linear probe; GE Medical Systems, Milwaukee, WI), as previously described (23, 30) . Briefly, following induction of anesthesia with 5% (vol/vol) isoflurane, the animal was laid supine while spontaneously breathing 2-3% (vol/vol) isoflurane through a modified face mask. A short-axis view of the heart was acquired at the level of the aortic valve, and the pulmonary artery was identified by color flow Doppler. The pulsed Doppler gate was placed proximal to the pulmonary valve leaflets and aligned with an insonation angle of Ͻ20°to obtain a Doppler profile. The pulmonary artery acceleration time (PAAT) was measured as the time from the onset of systolic flow to peak velocity and the RV ejection time (RVET) as the time from onset to completion of systolic flow. PVR index was derived using the formula, , which either is converted by LTA4 hydrolase to LTB4, or is conjugated by LTC4 synthase to produce cysteinyl (cys) LTs (LTC4, LTD4, and LTE4). Attenuated production of LTB4 by inhibition of 5-LPO with zileuton or by inhibition of LTA4 hydrolase with SC57461A prevented bleomycin-induced pulmonary hypertension. Antagonism of the cysLT1 receptor (cysLT1R), for which LTs C4, D4, and E4 act as ligands, had no effect on bleomycin-induced pulmonary hypertension.
RVET/PAAT. All values were averaged from three Doppler traces per animal using an offline analysis system (EchoPAC, GE Medical Systems). Histological studies. Lungs from six animals from each group (3 from each of 2 separate litters) were air-inflated and perfusion-fixed at constant pressure, embedded in paraffin, sectioned, and immunostained for CD68 (to identify macrophages), or were stained with hematoxylin-eosin, or for elastin, as previously described (23, 29, 33, 35) . For all analyses, measurements were carried out on four noncontiguous left lung sections per animal by an observer blinded to group identity. For assessment of percentage of arterial medial wall area, pulmonary arteries were identified by the presence of both inner and outer elastic lamina using Hart's elastin stain, as previously described in detail (14, 26) . Analyses of tissue macrophage (CD68-positive) cell numbers, mean linear intercept (using hematoxylin and eosin-stained sections), and counts of peripheral arteries (identified as vessels of external diameter between 20 and 65 m with both internal and external elastic laminae visible on elastin staining) were conducted as previously described in detail (28, 29, 33 ) from 10 random, nonoverlapping, low-power fields captured from each section. Paraformaldehyde-fixed cardiac ventricular tissues were also embedded in paraffin oriented in the short axis and stained with hematoxylin-eosin. For measurement of tissue neutrophils, immunostaining for MPO was performed as previously described (26) , and low-power images (10 per section, 2 sections per slide, and 2 slides per animal) were digitally captured using identical magnification, white balance settings, and exposure times. A tissue neutrophil index was derived representing the percentage of tissue area reaching a preset staining intensity threshold (for MPO-positive cells, normalized to total tissue area), using ImmunoRatio online software (http://153.1.200.58:8080/immunoratio).
Quantitative PCR. RNA was extracted and reverse transcribed, and quantitative PCR was performed as previously described (44) . Primer sequences of genes of interest are listed in Table 1 . A standard curve for each primer set was run to ensure that reaction efficiency was equivalent to primers for the housekeeping genes, ␤-actin and GAPDH, the expressions of which were determined in preliminary experiments to be unaffected by exposure to bleomycin. Samples were run in duplicate, and fold or fraction change in expression relative to control samples was calculated by the 2 Ϫ⌬ct method. ELISA. Lung lysates from six animals per group (3 from each of 2 separate litters) were purified and analyzed according to the manufacturer's instructions.
Western blot analyses. Lung tissues from six animals per group (3 from each of 2 separate litters) were lysed in RIPA buffer containing protease and phosphatase inhibitors. Samples were fractionated by SDS-PAGE, transferred to PVDF membranes, and blotted, and band densities were measured as previously described (18) . Differences in protein loading were compensated for by reblotting for GAPDH, the expression of which was found, in preliminary studies, to be unaffected by chronic exposure to bleomycin. Dilutions of primary antisera were 1:100 for FLAP, 1:200 for CCL4 and TNF-␣, 1:500 for MPO, 1:1,000 for 5-LPO and phospho-serine 271 5-LPO, 1:5,000 for GAPDH, and 1:10,000 for LTA4H and secondary antisera. Protein bands were identified using enhanced chemiluminescent substrate (SuperSignal West Dura, Thermo Fisher Scientific), and images were digitally captured using a MicroChemi chemiluminescent system (DNR Bio-imaging Systems, Jerusalem, Israel). Bands were quantified by digital densitometry of nonsaturated images with background density removed (ImageJ, NIH, Bethesda, MD).
Data presentation and analysis. All values are expressed as means Ϯ SE. Statistical analyses were performed using Sigma Plot 12.5 (Systat Software, San Jose, CA). Where three or more groups were compared, statistical significance (P Ͻ 0.05) was determined by one-way ANOVA, followed by pairwise multiple comparisons using the Tukey test. Where two groups were compared, the Student t-test was used. Table 2 , relative changes in mRNA expression were examined after 7 or 14 days of bleomycin (or vehicle) exposure. Relative to controls, exposure to bleomycin for 7 (but not 14) days led to significantly increased Alox5, Alox5ap, Ltc4s, Ltb4r, and Ltb4r2 mRNA expression. As shown in Fig. 2 , lung content of 5-LPO, FLAP, and LTA4H were also examined after 7 ( Fig. 2A) or 14 days (Fig. 2B) of bleomycin (or vehicle) exposure. Relative to vehicle, exposure to bleomycin for 7 days led to significantly increased lung content of 5-LPO and FLAP and no change in LTA4H (Fig. 2A) . In contrast, 5-LPO and FLAP content in bleomycin-exposed lungs was no longer significantly increased after 14 days, whereas there was a small, but significant, increase in lung LTA4H (Fig. 2B) . Lung content of phospho-serine 271 5-LPO did not differ between vehicle-and bleomycin-exposed animals at either time point (data not shown). Numbers of lung tissue (CD68-positive) macrophages (normalized to tissue fraction) secondary to bleomycin were increased by day 7 of exposure ( Fig. 2C) , to a similar extent as at day 14. As shown in Fig. 2D , tissue neutrophils were also increased in the bleomycin-exposed lung by 7 days, with a further significant increase at 14 days.
RESULTS
Temporal changes in effects of bleomycin on lung mRNA expression and protein content of key enzymes and receptors mediating LT signaling and on inflammatory cell influx. As shown in
Effects of bleomycin exposure and zileuton (5-LPO inhibitor) treatment on lung LTB 4 and CysLT content. Exposure to bleomycin for 7 days had no effect on LTB 4 content (data not shown); however, LTB 4 content was significantly increased after 14 days of bleomycin exposure (Fig. 3A) . The bleomycin-induced increase in LTB 4 at 14 days was completely prevented by treatment with zileuton (Fig. 3A) . CysLT (LTC 4 , LTD 4 , and LTE 4 ) contents were unaltered by bleomycin exposure or by zileuton treatment, both at 7 (data not shown) and at 14 days (Fig. 3B) .
Effects of zileuton on bleomycin-induced PHT. As previously reported (30, 44) , exposure to bleomycin for 14 days led to significantly increased PVR index (Fig. 4A), Fulton index (Fig.  4B) , and percentage of medial wall area in pulmonary resistance arteries (Fig. 4C) , relative to vehicle-treated controls. Treatment of bleomycin-exposed animals with zileuton restored these parameters to values comparable to controls (Fig. 4) .
Effects of montelukast (CysLT 1 R antagonist) or SC57461A (LTA4H inhibitor) on bleomycin-induced PHT.
Treatment with montelukast did not prevent bleomycin-induced PHT, as evidenced by a lack of effect on PVR (Fig. 5A ) and Fulton indexes (Fig. 5B ) or on percentage of medial wall area (Fig. 5C ). In contrast, treatment with SC57461A completely normalized PVR index (Fig. 5A ), Fulton index (Fig. 5B) , and percentage of medial wall area (Fig. 5C ). As shown in Fig. 5E , treatment with SC57461A completely prevented the bleomycin-induced increase in lung LTB 4 , which was unaffected by montelukast. To determine whether a lack of effect of montelukast on CysLT 1 R signaling was responsible for a failure to prevent bleomycininduced PHT, we examined lung content of CCL4 (also known as macrophage inflammatory protein-1␤), a chemokine known to be stimulated by CysLT 1 R activation (13) . Despite there being no increase in lung CysLT content secondary to bleomycin exposure (Fig. 3B) , CCL4 was found to be significantly increased in the bleomycin-exposed lung (Fig. 5F ). Increased lung CCL4 secondary to bleomycin was completely normalized by treatment with montelukast (Fig. 5F ), in keeping with effective blockade of the cysLT 1 R.
Effects of zileuton, montelukast, or SC57461A on bleomycininduced lung inflammation. The lungs of animals exposed to bleomycin had greatly increased CD68-positive cell numbers ( Fig. 6A ) and increased lung TNF-␣ content (Fig. 6B) . Treatment of bleomycin-exposed animals with zileuton or SC57461A significantly decreased tissue macrophage numbers (Fig. 6A) , while montelukast had no effect (Fig. 6A) . Treatment of bleomycin-exposed animals with zileuton also normalized lung TNF-␣ content (Fig. 6B ), in keeping with previous findings indicating that TNF-␣ is predominantly macrophage derived (44) . Treatment with zileuton also completely prevented neutrophil influx in the bleomycin-exposed lung (Fig. 6C) .
Effects of zileuton, montelukast, or SC57461A on bleomycininduced changes in lung morphology. As demonstrated by representative low-power elastin-stained sections (Fig. 7A) , the lung structure of bleomycin-exposed animals was characterized by septal thinning, arrested alveolarization [manifesting as "emphysematous" distal air spaces, quantified as increased mean chord length (Fig. 7B)] , and vascular hypoplasia (Fig.  7C) . Treatment with zileuton, montelukat, or SC57461A had no effects on these parameters (Fig. 7) .
DISCUSSION
In human preterm infants with respiratory distress, early increases in lung macrophages are known to persist in infants who develop severe BPD, while declining in those who do not (8). The potential role of LTs in this inflammatory process has received limited attention. We report in bleomycin-exposed neonatal rat pups, a model with similarities to human BPD, that treatment with zileuton, a 5-LPO inhibitor, or SC57461A, a LTA4H inhibitor, prevented upregulation of LTB 4 , inflammatory cell influx, and the hemodynamic and structural changes of chronic PHT. Our laboratory has previously shown that macrophagederived TNF-␣ is critical to bleomycin-induced chronic PHT (44) . In the present study, increased TNF-␣ was also attenuated by 5-LPO inhibition. Treatment with montelukast, a cysLT 1 R inhibitor, had no effect on macrophage influx or on markers of chronic PHT. These findings are in agreement with studies in adult experimental animals of inflammatory injury, which favor a dominant role for LTB 4 , rather than for cysLTs (49 -51) .
We did not observe any effects of LT pathway inhibition on arrested alveolarization or vascular hypoplasia. This divergence is consistent with our laboratory's own previous observations employing alternative interventions [e.g., therapeutic hypercapnia, arginase inhibition (15, 44) ] that were also efficacious in preventing inflammation and vascular remodeling, but not in preventing vascular hypoplasia or emphysematous lung structure. It appears, therefore, at least in bleomycinexposed neonatal rats, that inflammation and vascular remodeling are regulated by pathways distinct from those that regulate angiogenesis and alveologenesis. Whether this also holds true in humans remains unclear.
We observed increased mRNA expression of 5-LPO, FLAP, BLT1, and BLT2, which was confirmed at the protein level for 5-LPO and FLAP in the lungs of bleomycin-exposed animals. We did not observe increased lung content of phospho-serine 271 5-LPO, which increases 5-LPO activity and favors LTB 4 synthesis (41, 55) . Nonetheless, these changes were accompanied by increased lung LTB 4 in the bleomycin-exposed lung. The reasons for our observations regarding temporal changes in 5-LPO and FLAP (increased at day 7, but not at day 14) are unclear, but could represent a negative feedback effect of increased LTB 4 , which was only elevated at day 14. The degree of increase in LTB 4 secondary to bleomycin exposure was small, which we speculate may have reflected a dilutional effect inherent to measurement in whole tissue. LTB 4 has been previously described to be predominantly produced by inflammatory cells, particularly activated macrophages and neutrophils (32, 50) , which are both present in abundance in the bleomycin-exposed lung (15, 26, 30, 44) . In the present study, we were unable to determine the cellular sources of LTB 4 , due to a lack of commercially available antibodies suitable for in situ immunostaining. However, it appears unlikely that macrophages are a major source of LTB 4 in the lungs of bleomycin-exposed neonatal rats, given our present findings that tissue macrophage numbers plateaued by 7 days of bleomycin exposure when LTB 4 was not increased. Increased LTB 4 production by pulmonary artery endothelial cells has also been described (32, 50) . As nonmyeloid cells are poor in 5-LPO, LT production in such cells is believed to be facilitated by intercellular transfer of LTA 4 (12, 32, 50) . The pattern of temporal changes in inflammatory cell number and the observation that treatment with zileuton decreased both macrophage and neutrophil influx opens the possibility that one inflammatory cell type may recruit the other, particularly that macrophages may recruit neutrophils; however, our laboratory's previous work in the present model suggests that this is not the case. For example, an intervention (therapeutic hypercapnia) that prevented macrophage influx had no effect on tissue neutrophils (44) . Conversely, a CXCR2 antagonist intervention that prevented neutrophil influx had no effect on increased tissue macrophages or on the development of PHT (26) .
Our present results are consistent with previous work by Tian and colleagues (51) , in which blockade of LTA4H-expressing macrophages prevented endothelial injury and reversed PHT in sugen-exposed, athymic rats. Based on in vitro observations, the suggested mechanism of LTB 4 -mediated injury was endothelial cell apoptosis via inhibited expression of sphingosine-1-phosphate and endothelial nitric oxide synthase (51) . Whether changes in sphingosine-1-phosphate and endothelial nitric oxide synthase represented a direct effect of LTB 4 or the result of limiting macrophage influx and thereby other macrophage-derived products was unclear. LTB 4 has also been reported to stimulate pulmonary artery smooth muscle cell proliferation and migration (17) and to activate adventitial fibroblasts (40) , thus potentially playing a direct role in vascular remodeling.
There are several limitations to this study. First, a major feature of bleomycin-induced lung injury is collagen deposition, which is not a consistent feature of modern BPD. Our use of this model was predicated on a striking degree of arrested lung growth and development, which is disproportionate to the effects on other organs, despite systemic administration (53) . Second, our intervention studies demonstrating an effect in preventing chronic PHT were limited to inhibition of 5-LPO and LTA4H. Confirmation of the marked upregulation of BLT1 mRNA in the bleomycin-exposed lung at the protein level, localization of BLT1-expressing cells in the bleomycinexposed lung, and further intervention studies employing specific BLT1 antagonists (17, 40, 51) are a focus of ongoing and future work. The cellular localization of LT pathway mediators upregulated in the bleomycin-exposed lung and whether LTB 4 plays a direct role in the pathogenesis of vascular remodeling, in addition to an indirect role via macrophages, are also issues worthy of future consideration. Finally, our early preventive strategy in the present study was to treat throughout the 14-day period of injury. As macrophage influx in this model plateaued by 7 days of life, it is possible that a shorter duration of therapy may be sufficient to confer a protective effect.
In conclusion, LTB 4 , but not cysLTs, appears to play a crucial role in lung inflammation and PHT in experimental BPD-like injury secondary to systemic bleomycin. Agents targeting LTB 4 or LTB 4 -mediated signaling may have utility in human infants at risk of developing BPD-associated PHT. 
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